Gastric cancer treatment: recent progress and future perspectives

Wen‐Long Guan, Ye He, Rui‐Hua XuJournal of Hematology & Oncology 2023 · DOI

Abstract

Gastric cancer (GC) is one of the most common malignancies worldwide. Most patients are diagnosed at advanced stages due to the subtle symptoms of earlier disease and the low rate of regular screening. Systemic therapies for GC, including chemotherapy, targeted therapy and immunotherapy, have evolved significantly in the past few years. For resectable GC, perioperative chemotherapy has become the standard treatment. Ongoing investigations are exploring the potential benefits of targeted therapy or immunotherapy in the perioperative or adjuvant setting. For metastatic disease, there have been notable advancements in immunotherapy and biomarker-directed therapies recently. Classification based on molecular biomarkers, such as programmed cell death ligand 1 (PD-L1), microsatellite instability (MSI), and human epidermal growth factor receptor 2 (HER2), provides an opportunity to differentiate patients who may benefit from immunotherapy or targeted therapy. Molecular diagnostic techniques have facilitated the characterization of GC genetic profiles and the identification of new potential molecular targets. This review systematically summarizes the main research progress in systemic treatment for GC, discusses current individualized strategies and presents future perspectives.

Introduction

Gastric cancer (GC) remains a formidable challenge in global oncology, currently ranking as the fourth leading cause of cancer-related mortality. Historically, the prognosis for advanced GC was poor, with standard systemic chemotherapy offering a median overall survival (OS) of only about 12 months. The primary obstacle to effective treatment is the extreme heterogeneity of the disease, which manifests both between different patients and within individual tumors. This review explores the transition from a "one-size-fits-all" approach to a precision medicine paradigm, driven by the identification of key molecular biomarkers.

The Evolving Landscape of Systemic Therapy

The current treatment landscape for GC is categorized into perioperative/adjuvant therapy, immunotherapy, and targeted therapy. Landmark clinical trials have established new standards of care across these domains. For instance, the FLOT4-AIO and RESOLVE trials have defined perioperative chemotherapy regimens (like FLOT and SOX) that significantly improve survival in resectable GC. In the metastatic setting, trials such as CheckMate-649 and KEYNOTE-859 have demonstrated the efficacy of first-line immunotherapy, while the ToGA and DESTINY-Gastric01 trials have solidified the role of HER2-targeted agents.

Precision Medicine and Molecular Biomarkers

The shift toward individualized treatment is predicated on the characterization of GC genetic profiles. Key biomarkers now include human epidermal growth factor receptor 2 (HER2), programmed cell death ligand 1 (PD-L1), and microsatellite instability (MSI).

Overview of therapeutic targets and associated drugs in gastric cancer treatment.

Immunotherapy and the MSI-H Subtype

Patients with Microsatellite Instability-High (MSI-H) tumors represent a unique "super-responder" group. These patients derive substantial benefit from immune checkpoint inhibitors (ICIs) like Nivolumab and Pembrolizumab. Interestingly, evidence suggests that MSI-H patients may have a poorer prognosis with standard chemotherapy alone, prompting a potential shift where immunotherapy might eventually allow some patients to achieve a complete pathological response (pCR) without the need for surgery.

The Rise of Antibody-Drug Conjugates (ADCs)

Antibody-Drug Conjugates (ADCs) represent a significant technological leap in targeted therapy. Drugs like Trastuzumab deruxtecan (T-DXd) combine an antigen-specific antibody with a potent cytotoxic payload.

Mechanism of an Antibody-Drug Conjugate (ADC) featuring an antigen-specific backbone and cytotoxic payload.

ADCs are particularly effective because of the "bystander effect," which allows the cytotoxic payload to kill neighboring cancer cells even if they do not express the target receptor. This mechanism is crucial for addressing the inherent heterogeneity of gastric tumors.

Emerging Targets: Claudin 18.2

Beyond HER2, Claudin 18.2 (CLDN18.2) has emerged as a highly promising target, particularly for diffuse-type gastric cancer. The Phase III SPOTLIGHT and GLOW trials for Zolbetuximab have shown significant improvements in OS, marking the first major success for a non-HER2 targeted therapy in the first-line setting.

Key Clinical Outcomes

  • Perioperative FLOT: Improved median OS to 50 months, compared to 35 months with older ECF/ECX regimens.
  • First-line Immunotherapy: In CheckMate-649, Nivolumab plus chemotherapy improved OS to 14.4 months in patients with a PD-L1 Combined Positive Score (CPS) ≥ 5.
  • HER2-Targeted ADCs: T-DXd showed an Objective Response Rate (ORR) of 51% in the third-line setting (DESTINY-Gastric01).
  • Claudin 18.2: Zolbetuximab plus mFOLFOX6 extended median OS to 18.23 months in the SPOTLIGHT trial.

Future Directions and Challenges

Despite these breakthroughs, several challenges persist. There is an ongoing need for biomarker standardization, particularly regarding PD-L1 "cut-off" scores. Furthermore, tumors frequently develop resistance by losing target expression or activating bypass signaling pathways.

Future progress will likely rely on "multi-omics" integration—combining genomic, proteomic, and clinical data—and the broader implementation of liquid biopsies (ctDNA) for monitoring minimal residual disease. Additionally, AI-driven platforms like GRAIDS offer hope for improving early detection rates, which remains the most effective way to improve long-term outcomes in gastric cancer.

Summary updated

Abstract

Gastric cancer (GC) is one of the most common malignancies worldwide. Most patients are diagnosed at advanced stages due to the subtle symptoms of earlier disease and the low rate of regular screening. Systemic therapies for GC, including chemotherapy, targeted therapy and immunotherapy, have evolved significantly in the past few years. For resectable GC, perioperative chemotherapy has become the standard treatment. Ongoing investigations are exploring the potential benefits of targeted therapy or immunotherapy in the perioperative or adjuvant setting. For metastatic disease, there have been notable advancements in immunotherapy and biomarker-directed therapies recently. Classification based on molecular biomarkers, such as programmed cell death ligand 1 (PD-L1), microsatellite instability (MSI), and human epidermal growth factor receptor 2 (HER2), provides an opportunity to differentiate patients who may benefit from immunotherapy or targeted therapy. Molecular diagnostic techniques have facilitated the characterization of GC genetic profiles and the identification of new potential molecular targets. This review systematically summarizes the main research progress in systemic treatment for GC, discusses current individualized strategies and presents future perspectives.
BibTeX
@article{guan2023gastric,
  author = {Wen‐Long Guan and Ye He and Rui‐Hua Xu},
  title = {{Gastric cancer treatment: recent progress and future perspectives}},
  journal = {Journal of Hematology \& Oncology},
  year = {2023},
  doi = {10.1186/s13045-023-01451-3},
}
Figure